The FDA is still reviewing the EUA submission for Moderna’s booster shot, where the only remaining issue is the dose. MRNA thinks a dose half as much as the dose used for the first two shots would suffice for the booster, but the FDA may want to go with the full dose.
According to newswires today, the FDA is leaning toward a half-dose (50 mcg) MRNA booster, which is probably more than sufficient from an efficacy standpoint.